Latest Pneumococcal conjugate vaccine Stories
SAN DIEGO, May 17, 2011 /PRNewswire/ -- Pfenex Inc.'s Reagent Proteins division announced today that it has submitted a Biologics Master File (BMF) to the United States Food and Drug Administration for its cGMP grade CRM197 carrier protein to support the development of conjugate vaccine products by its partners. Reagent Proteins is supplying cGMP grade CRM197 carrier protein to multiple partners in support of their novel conjugate vaccine development efforts.
SWIFTWATER, Pa., April 22, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S.
Using a cross-sectional study, Stefan Flasche and colleagues investigated the effects of the UK pneumococcal vaccination program on serotype-specific carriage and invasive pneumococcal disease.
BEIJING, March 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
Two widely-used vaccines made by Pfizer and Sanofi-Aventis have been suspended for use in Japan, as the health ministry investigates whether they are linked to the recent deaths of four infants.
BEIJING, March 3, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
Researchers at Albert Einstein College of Medicine of Yeshiva University have developed an experimental vaccine that appears to protect against an increasingly common and particularly deadly form of pneumococcal pneumonia.
Pneumococcus (Streptococcus pneumoniae) accounts for as much as 11 percent of mortality in young children worldwide.
Experts say that children will be better protected against pneumonia and other infections caused by the pneumococcus bacterium with this year's updated immunization schedule.
BEIJING, Jan. 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.